论文部分内容阅读
应用免疫组化方法对１１例鼻咽部恶性淋巴瘤、１０例鼻咽部低分化癌、８例鼻咽部反应性淋巴组织增生进行了上皮性标记（Ｋｅｒａｔｉｎ、、ＥＭＡ）、淋巴组织标记（ＬＣＡ、Ｌ２６、ＤＣＨＬ１）及免疫球蛋白（Ｋ轻链、λ轻链）标记。结果发现：①恶性淋巴瘤ＬＯＡ９１％阳性，Ｋｅｒａｔｉｎ、ＥＭＡ阴性；低分化癌ＬＣＡ阴性，Ｋｅｒａｔｉｎ、ＢＭＡ阳性；②Ｂ细胞性淋巴瘤，Ｋ轻链阳性或λ轻链阳性占８２％，呈单克隆表型；而反应性增生，Ｋ轻链λ轻链均阳性，呈多克隆表型；③淋巴瘤的分型：Ｌ２６阳性６例，提示Ｂ细胞性淋巴瘤；ＵＣＨＬ１阳性４例，提示为Ｔ细胞性淋巴瘤，Ｔ：Ｂ为１：１．５。初步认为免疫组化有助于鼻咽部恶性淋巴瘤的诊断及鉴别诊断，并探讨其组织来源以指导临床制定合理的治疗方案及判断预后。
Immunohistochemical methods were used to identify 11 cases of malignant lymphoma of the nasopharynx, 10 cases of poorly differentiated nasopharyngeal carcinoma, and 8 cases of reactive lymphoid hyperplasia of the nasopharyngeal epithelium (Keratin, EMA) and lymphoid tissue markers ( LCA, L26, DCHL1) and immunoglobulin (K light chain, lambda light chain) tag. The results showed that: 1 malignant lymphoma LOA91% positive, negative for Keratin, EMA; poorly differentiated carcinoma negative LCA, Keratin, BMA positive; 2 B cell lymphoma, K light chain positive or lambda light chain positive accounted for 82%, was a monoclonal table Type; Reactive hyperplasia, K light chain λ light chain positive, polyclonal phenotype; 3 Lymphoma type: 6 cases of L26 positive, suggesting B-cell lymphoma; UCHL1 positive 4 cases, suggesting T cells Lymphoma, T:B is 1:1.5. It is initially thought that immunohistochemistry contributes to the diagnosis and differential diagnosis of nasopharyngeal malignant lymphomas, and explores their tissue sources to guide clinical development of reasonable treatment plans and prognosis.